Japan Cell and Gene Therapy Market Growth, Size, Trends Analysis- By Therapy Type, By Indication, By Delivery Mode, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033

Description

Japan Cell and Gene Therapy Market Introduction and Overview

According to SPER Market Research, 'Japan Cell and Gene Therapy Market Size- By Therapy Type, By Indication, By Delivery Mode, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2033' states that the Japan Cell and Gene Therapy Market is estimated to reach USD 9744.68 million by 2033 with a CAGR of 12.71%.

Cell and gene therapy are cutting-edge medical treatments with immense promise for treating a wide range of diseases and maladies. In essence, cell therapy is the transplantation or manipulation of living cells to replace or repair damaged or dysfunctional tissues in the human body. This may include using stem cells to restore damaged organs or tissues. On the other hand, gene therapy focuses on modifying or correcting faulty genes that cause disease.

COVID-19 Impact on Japan Cell and Gene Therapy Market

The COVID-19 pandemic has had a substantial influence on the cell and gene therapy manufacturing sector.

Accelerated Research and Development - The pandemic has spurred research and development of cell and gene treatments, which have the potential to treat COVID-19 and related problems.

Scope of the report:

Report Metric Details

Market size available for years 2020-2033

Base year considered 2023

Forecast period 2024-2033

Segments covered By Therapy Type, By Indication, By Delivery Mode, By End User

Regions covered Kanto Region, Kansai/Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, Shikoku Region.

Companies Covered Bristol-Myers Squibb Company, 2seventy bio, Inc, Novartis AG, Gilead Sciences Inc (Kite Pharma), Spark Therapeutics, Inc, Nipro Corporation, JCR Pharmaceuticals Co., Ltd, Aurion Biotech, Johnson & Johnson Services, Inc, Terumo BCT.

Japan Cell and Gene Therapy Market Segmentation:

By Therapy Type: Based on the Therapy Type, Japan Cell and Gene Therapy Market is segmented as; Cell Therapy, Gene Therapy.

By Indication: Based on the Indication, Japan Cell and Gene Therapy Market is segmented as; Cardiovascular Disease, Oncology Disorder, Genetic Disorder, Infectious Disease, Neurological Disorder, and Others.

By Delivery Mode: Based on the Delivery Mode, Japan Cell and Gene Therapy Market is segmented as; In-Vivo, Ex-Vivo.

By End User: Based on the End User, Japan Cell and Gene Therapy Market is segmented as; Hospitals, Cancer Care Centers, Pharmaceutical and Biotechnology Companies, and Others.

Product Code: HLCA2495

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPER's internal database
- 2.1.4. Premium insight from KOL's
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
4.2. COVID-19 Impacts of the Japan Cell and Gene Therapy Market.

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTER's Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Japan Cell and Gene Therapy Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Japan Cell and Gene Therapy Market

7. Japan Cell and Gene Therapy Market, By Therapy Type (USD Million) 2020-2033

7.1. Japan Cell and Gene Therapy Market Size, Share and Forecast, By Therapy Type, 2020-2026
7.2. Japan Cell and Gene Therapy Market Size, Share and Forecast, By Therapy Type, 2027-2033
7.3. Cell Therapy
- 7.3.1. Stem Cell
- 7.3.2. Non-Stem Cell
7.4. Gene Therapy

8. Japan Cell and Gene Therapy Market, By Indication (USD Million) 2020-2033

8.1. Japan Cell and Gene Therapy Market Size, Share and Forecast, By Indication, 2020-2026
8.2. Japan Cell and Gene Therapy Market Size, Share and Forecast, By Indication, 2027-2033
8.3. Cardiovascular Disease
8.4. Oncology Disorder
8.5. Genetic Disorder
8.6. Infectious Disease
8.7. Neurological Disorder
8.8. Others

9. Japan Cell and Gene Therapy Market, By Delivery Mode (USD Million) 2020-2033

9.1. Japan Cell and Gene Therapy Market Size, Share and Forecast, By Delivery Mode, 2020-2026
9.2. Japan Cell and Gene Therapy Market Size, Share and Forecast, By Delivery Mode, 2027-2033
9.3. In-Vivo
9.4. Ex-Vivo

10. Japan Cell and Gene Therapy Market, By End User (USD Million) 2020-2033

10.1. Japan Cell and Gene Therapy Market Size, Share and Forecast, By End User, 2020-2026
10.2. Japan Cell and Gene Therapy Market Size, Share and Forecast, By End User, 2027-2033
10.3. Hospitals
10.4. Cancer Care Centers
10.5. Pharmaceutical and Biotechnology Companies
10.6. Others

11. Japan Cell and Gene Therapy Market Forecast, 2020-2033 (USD Million)

11.1. Japan Cell and Gene Therapy Market Size and Market Share

12. Japan Cell and Gene Therapy Market, By Region, 2020-2033 (USD Million)

12.1. Japan Cell and Gene Therapy Market Size and Market Share By Region (2020-2026)
12.2. Japan Cell and Gene Therapy Market Size and Market Share By Region (2027-2033)
12.3. Kanto Region
12.4. Kansai/Kinki Region
12.5. Central/ Chubu Region
12.6. Kyushu-Okinawa Region
12.7. Tohoku Region
12.8. Chugoku Region
12.9. Hokkaido Region
12.10. Shikoku Region

13. Company Profile

13.1. Bristol-Myers Squibb Company
- 13.1.1. Company details
- 13.1.2. Financial outlook
- 13.1.3. Product summary
- 13.1.4. Recent developments
13.2. 2seventy bio, Inc
- 13.2.1. Company details
- 13.2.2. Financial outlook
- 13.2.3. Product summary
- 13.2.4. Recent developments
13.3. Novartis AG
- 13.3.1. Company details
- 13.3.2. Financial outlook
- 13.3.3. Product summary
- 13.3.4. Recent developments
13.4. Gilead Sciences Inc
- 13.4.1. Company details
- 13.4.2. Financial outlook
- 13.4.3. Product summary
- 13.4.4. Recent developments
13.5. Spark Therapeutics, Inc
- 13.5.1. Company details
- 13.5.2. Financial outlook
- 13.5.3. Product summary
- 13.5.4. Recent developments
13.6. Nipro Corporation
- 13.6.1. Company details
- 13.6.2. Financial outlook
- 13.6.3. Product summary
- 13.6.4. Recent developments
13.7. JCR Pharmaceuticals Co., Ltd
- 13.7.1. Company details
- 13.7.2. Financial outlook
- 13.7.3. Product summary
- 13.7.4. Recent developments
13.8. Aurion Biotech
- 13.8.1. Company details
- 13.8.2. Financial outlook
- 13.8.3. Product summary
- 13.8.4. Recent developments
13.9. Johnson & Johnson Services, Inc
- 13.9.1. Company details
- 13.9.2. Financial outlook
- 13.9.3. Product summary
- 13.9.4. Recent developments
13.10. Terumo BCT
- 13.10.1. Company details
- 13.10.2. Financial outlook
- 13.10.3. Product summary
- 13.10.4. Recent developments
13.11. Others